全文获取类型
收费全文 | 67742篇 |
免费 | 5462篇 |
国内免费 | 1876篇 |
专业分类
耳鼻咽喉 | 324篇 |
儿科学 | 2747篇 |
妇产科学 | 3190篇 |
基础医学 | 9748篇 |
口腔科学 | 1209篇 |
临床医学 | 5027篇 |
内科学 | 9150篇 |
皮肤病学 | 1030篇 |
神经病学 | 5090篇 |
特种医学 | 1060篇 |
外国民族医学 | 6篇 |
外科学 | 5695篇 |
综合类 | 8847篇 |
现状与发展 | 5篇 |
一般理论 | 3篇 |
预防医学 | 4963篇 |
眼科学 | 772篇 |
药学 | 8882篇 |
19篇 | |
中国医学 | 3105篇 |
肿瘤学 | 4208篇 |
出版年
2024年 | 164篇 |
2023年 | 1213篇 |
2022年 | 2755篇 |
2021年 | 2983篇 |
2020年 | 2459篇 |
2019年 | 2631篇 |
2018年 | 2605篇 |
2017年 | 2507篇 |
2016年 | 2237篇 |
2015年 | 2298篇 |
2014年 | 3868篇 |
2013年 | 4433篇 |
2012年 | 3421篇 |
2011年 | 4122篇 |
2010年 | 3253篇 |
2009年 | 3220篇 |
2008年 | 3223篇 |
2007年 | 3002篇 |
2006年 | 2913篇 |
2005年 | 2611篇 |
2004年 | 2312篇 |
2003年 | 2002篇 |
2002年 | 1608篇 |
2001年 | 1270篇 |
2000年 | 1212篇 |
1999年 | 1015篇 |
1998年 | 866篇 |
1997年 | 816篇 |
1996年 | 717篇 |
1995年 | 685篇 |
1994年 | 553篇 |
1993年 | 493篇 |
1992年 | 389篇 |
1991年 | 393篇 |
1990年 | 317篇 |
1989年 | 277篇 |
1988年 | 321篇 |
1987年 | 232篇 |
1986年 | 243篇 |
1985年 | 434篇 |
1984年 | 438篇 |
1983年 | 334篇 |
1982年 | 402篇 |
1981年 | 320篇 |
1980年 | 288篇 |
1979年 | 245篇 |
1978年 | 195篇 |
1977年 | 145篇 |
1976年 | 162篇 |
1975年 | 146篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
31.
32.
Kelly H. M. Cooijmans Roseriet Beijers Bonnie E. Brett Carolina de Weerth 《Maternal & child nutrition》2022,18(1):e13241
This randomized controlled trial evaluated the effect of a 5-week daily skin-to-skin contact (SSC) intervention between mothers and their full-term infants, compared with care-as-usual, on exclusive and continued breastfeeding duration during the first post-natal year. Healthy pregnant women (n = 116) from a community sample were enrolled and randomly allocated to the SSC or care-as-usual condition. SSC mothers were requested to provide one daily hour of SSC for the first five post-natal weeks. Twelve months post-partum, mothers indicated the number of exclusive and continued breastfeeding months. Multiple regression analyses were conducted using intention-to-treat, per-protocol and exploratory dose–response frameworks. In intention-to-treat analyses, exclusive and continued breastfeeding duration was not different between groups (exclusive: 3.61 ± 1.99 vs. 3.16 ± 1.77 months; adjusted mean difference 0.28, 95% confidence interval [CI] ?0.33 to 0.89; p = 0.36; continued: 7.98 ± 4.20 vs. 6.75 ± 4.06 months; adjusted mean difference 0.81, 95% CI ?0.46 to 2.08; p = 0.21). In per-protocol analyses, exclusive and continued breastfeeding duration was longer for SSC than care-as-usual dyads (exclusive: 4.89 ± 1.26 vs. 3.25 ± 1.80 months; adjusted mean difference 1.28, 95% CI 0.31–2.24; p = 0.01; continued: 10.81 ± 1.97 vs. 6.98 ± 4.08 months; adjusted mean difference 2.33, 95% CI 0.13–4.54; p = 0.04). Exploratory dose–response effects indicated that more SSC hours predicted longer exclusive and continued breastfeeding duration. This study demonstrates that for the total group, the 5-week daily SSC intervention did not extend exclusive and continued breastfeeding duration. However, for mothers performing a regular daily hour of SSC, this simple and accessible intervention may extend exclusive and continued breastfeeding duration by months. Future studies are required to confirm these promising findings. Trial registration: Netherlands Trial Register (NTR5697). 相似文献
33.
35.
《Clinical Lymphoma, Myeloma & Leukemia》2022,22(8):608-617
BackgroundConsiderable progress has been made in therapeutic options for multiple myeloma (MM). Understanding the current landscape of MM treatment options and associated outcomes in the real world is important in providing key insights into clinical and knowledge gaps which could be targeted for further optimization.MethodsThe Canadian Myeloma Research Group Database (CMRG-DB) is a prospectively maintained disease-specific database with >7000 patients. The objective of this study was to describe the trends in the treatment landscape and outcomes including early mortality, time to next treatment, and overall survival (OS) in each line of treatment stratified by autologous stem cell transplant (ASCT) receipt among newly-diagnosed MM patients in Canada between 2007 and 2018.ResultsA total of 5154 patients were identified among which 3030 patients (58.8%) received an upfront ASCT and 2124 (41.2%) did not. At diagnosis, the median age was 64 years and 58.6% were males. Bortezomib and lenalidomide were most frequently used (>50%) in first and second-line treatment respectively among both the ASCT and non-ASCT cohort. The median OS was 122.0 months (95% Cl 115.0-135.0 months) and 54.3 months (95% CI 50.8-58.8 months) for the ASCT and non-ASCT cohort respectively with an incremental decrease in OS in each subsequent line of treatment.ConclusionWe present the largest study to date in the Canadian landscape showing the characteristics, therapy usage, and outcomes among MM patients. This information will be critical in benchmarking current outcomes and provide key insight into areas of unmet needs and gaps for improvement of MM patients nationally. 相似文献
36.
37.
Deoxynivalenol (DON) has broad toxicity in animals and humans. In this study the impact of DON treatment on apoptotic pathways in PC12 cells was determined. The effects of DON were evaluated on (i) typical indicators of apoptosis, including cellular morphology, cell activity, lactate dehydrogenase (LDH) release, and apoptosis ratio in PC12 cells, and on (ii) the expression of key genes and proteins related to apoptosis, including Bcl-2, Bax, Bid, cytochrome C (Cyt C), apoptosis inducing factor (AIF), cleaved-Caspase9, and cleaved-Caspase3. DON treatment inhibited proliferation of PC12 cells, induced significant morphological changes and apoptosis, promoted the release of Cyt C and AIF from the mitochondria, and increased the activities of cleaved-Caspase9 and cleaved-Caspase3. Bcl-2 expression decreased with increasing DON concentrations, in contrast to Bax and Bid, which were increased with increasing DON concentration. These data demonstrate that DON induces apoptosis in PC12 cells through the mitochondrial apoptosis pathway. 相似文献
38.
39.
40.